Medical therapy for gastroesophageal reflux disease in 2007

Reviews in Gastroenterological Disorders

Volumn 7, Issue 4, 2007, Pages 193-203

  Katz, Philip O ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Antisecretory therapy; Gastroesophageal reflux disease; Histamine2 receptor antagonists; Non acid reflux; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; BACLOFEN; BETHANECHOL; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR; SUCRALFATE; TEGASEROD;

ABDOMINAL PAIN; AGITATION; AMENORRHEA; ANXIETY DISORDER; BEDTIME DOSAGE; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; GALACTORRHEA; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; HYPERPROLACTINEMIA; IRRITABLE COLON; LIFESTYLE MODIFICATION; MASTALGIA; MONOTHERAPY; PHARMACODYNAMICS; REFLUX ESOPHAGITIS; RESTLESSNESS; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH PH; TARDIVE DYSKINESIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 37849037649     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965-971.
2. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200.
3. Hila A, Castell DO. Nighttime reflux is primarily an early event. J Clin Gastroenterol. 2005;39:579-583.
4. Dickman R, Malagon I, Han B, et al. Comparison of acid reflux characteristics through the sleep period among different gastroesophageal reflux disease (GERD) groups [abstract]. Am J Gastroenterol. 2006;101:S44.
5. Tytgat GNJ, Nio CY. The medical therapy of reflux oesophagitis. Bailleres Clin Gastroenterol. 1987;1:791.
6. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacologic management of gastro-oesophageal reflux disease. Drugs. 1995;49:695-710.
7. Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis. Hepatogastroenterology. 1985;32:181.
8. Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med. 1987;83:43.
9. Hameeteman W, van de Boomgaard DM, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis: single blind multicenter study. J Clin Gastroenterol. 1987;9:390-394.
10. Madanick RD, Katz PO. GERD and pregnancy. Prac Gastroenterol. 2006;XXIX:30-39.
11. McCallum RW, Ippoliti AF, Cooner C, et al. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med. 1977;296:354.
12. Bright-Asare P, El-Bassoussi M. Cimetidine, metoclopramide or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol. 1980;2:149.
13. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993;7:5-20.
14. Xue S, Baidoo L, DiPietro M, et al. Lansoprazole reduces symptoms, esophageal acid exposure, and heals esophagitis in scleroderma patients. Gastroenterology. 2002;122:A1279.
15. Blackwell JN, Heading RC, Fettes MR. Effects of domperidone on lower oesophageal sphincter pressure and gastro-oesophageal reflux in patients with peptic esophagitis. Progress with domperidone. Royal Society of Medicine. International Congress and Symposium Series. 1981;36:57.
16. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophagael acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:1503-1509.
17. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol. 2006;4:442-450.
18. Bell NJV, Burget DL, Howden CW, et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion. 1992;51(suppl 1):59.
19. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007;25:617-628.
20. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(suppl 1):9-31.
21. Chiba N, De Gara CJ, Wilkonson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798.
22. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335-1339.
23. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
24. Tutuian R, Katz PO, Ahmed F, et al. Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Aliment Pharmacol Ther. 2002;16:473-477.
25. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther. 1999;13:675-678.
26. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235-1240.
27. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther. 2000;14:1049-1056.
28. Castell D, Bagin R, Goldlust B, et al. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21:1467-1474.
29. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25:197-205.
30. Product information for all proton pump inhibitors. Physicians' Desk Reference, 60th ed. Montvale, NJ: Thomson PDR; 2006.
31. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341-1349.
32. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30:29-33.
33. Laheij RJF, Sturkenboom MCHM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960.
34. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33-38.
35. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA. 294:2989-2995.
36. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3-10.
37. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.
38. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-781.
39. Klinkenberg-Knol E, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastro-esophageal reflux disease. Gastroenterology. 2000;118:661-669.
40. Tutuian R, Katz PO, Castell DO. A PPI is a PPI is a PPI: lessons from prolonged intragastric pH monitoring. Gastroenterology. 2000;118:A17.
41. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616-2620.
42. Hatlebakk JG, Katz PO, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272.
43. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024-1031.
44. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastro-esophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
45. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17:243-251.
46. Tutuian R, Mainie I, Agrawal A, et al. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest. 2006;130:386-391.
47. Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol. 2006;4:431-432.
48. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93:1483-1487.
49. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656-665.
50. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
51. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21:739-746.